Xconomy -- San Jose, CA-based Chronix Biomedical, a developer of tests that can detect cancer and neurologic diseases from DNA circulating in the blood, has raised $2.8 million in a sale of equity and options, according to a regulatory filing. The round’s 11 investors are not identified, but the company’s previous backers include Prairie Gold Venture Partners in Sioux Falls, SD.
